In-vitro activity of FCE 22101 against respiratory tract pathogens with reference to production of -lactamases

Publisher Website
Google Scholar
Abstract
FCE 22101 is a new penem with broad antibacterial spectrum, excluding the pseudomonads, and has stability to many β -lactamases. FCE 22101 and imipenem were very potent against the bacteria studied, including β -lactamase producing strains, which can be isolated from patients with respiratory tract infections (MIC≤8 mg/l). No strains were found to be resistant to FCE 22101. FCE 22101 was rapidly bactericidal and more stable to ihactivation by β -lactamases from Branhamella catarrhalis. Haemophilia influenzae, Ertterobacter cloacae and Klebsiella pneumoniae than imipenem and ceftibuten. The other antibiotics tested varied in their activities against the respiratory tract pathogens.

This publication has 0 references indexed in Scilit: